IOL Chemicals & Pharmaceuticals has successfully completed strategic capacity expansions across its chemical manufacturing operations, with both projects concluded on March 2, 2026. The company disclosed the completion details through a regulatory filing under Regulation 30 of SEBI Listing Regulations, revealing a total investment of ₹9.71 crore funded through internal accruals.

Completed Capacity Expansions

The company has successfully implemented capacity improvements across two key manufacturing facilities:

Operational Performance and Rationale

The expansion projects were undertaken based on strong operational fundamentals. The ethyl acetate facility was operating at 100% capacity utilization, while the acetic anhydride facility maintained above 90% utilization levels. The company cited sustained growth in demand from various sectors and improved margin realization through optimum operating leverage as key drivers for the ethyl acetate expansion.

Investment and Financing Details

The total capital expenditure of ₹9.71 crore was entirely funded through internal accruals, demonstrating the company's strong cash generation capabilities. The ethyl acetate expansion required ₹4.00 crore investment, while the acetic anhydride capacity enhancement involved ₹5.71 crore expenditure.

Strategic Impact

The ethyl acetate capacity enhancement represents a 20% increase from the previous production level, strengthening IOL Chemicals' position in this market segment. For acetic anhydride, the company aims to optimize both captive usage and merchant sales with the additional 7,000 MTPA capacity. These completed expansions enhance IOL Chemicals & Pharmaceuticals' competitive position in the chemical industry through strategic capital allocation and operational excellence.

IOL Chemicals & Pharmaceuticals has received regulatory approval from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Clopidogrel Besilate Active Pharmaceutical Ingredient (API). The company announced this development through an official filing with stock exchanges, under Regulation 30 of SEBI listing requirements.

Regulatory Certification Details

The EDQM granted the Certificate of Suitability (CEP) for IOL Chemicals' Clopidogrel Besilate API on February 23, 2026. This approval adds to the company's existing regulatory credentials, as it already holds a valid CEP for Clopidogrel Bisulphate.

Strategic Significance

The Certificate of Suitability from EDQM is a crucial regulatory document that demonstrates compliance with European Pharmacopoeia standards. This certification enables pharmaceutical companies to market their APIs across European Union member states, providing significant market access opportunities.

Clopidogrel is an antiplatelet medication used in the treatment and prevention of cardiovascular diseases, making it a critical component in the pharmaceutical supply chain.

Product Portfolio Enhancement

With certifications for both Clopidogrel Besilate and Clopidogrel Bisulphate APIs, IOL Chemicals has strengthened its position in the cardiovascular medication segment. The dual CEP certifications position the company to serve European pharmaceutical manufacturers requiring these critical APIs for their formulation needs.

The regulatory approval enhances the company's pharmaceutical portfolio and demonstrates its commitment to maintaining high-quality standards in API manufacturing for international markets.